Hello! We are Depixus®

Introducing our work

Depixus® is undertaking commercial development of a technology for the fast, accurate, and inexpensive extraction of genetic and epigenetic information from single molecules of DNA and RNA. The technology is known as MAGNA™ (SIngle-molecule Magnetic DEtection and Quantification). It was initially developed in the laboratory of Vincent Croquette, David Bensimon, and Jean-François Allemand at École Normale Supérieure (ENS), one of France’s leading ‘grandes écoles’.

MAGNA™ has a wide range of potential applications across the life-science and medical industries. Using the MAGNA™ platform, it will be possible to identify, count, fully sequence, and epitype many millions of individual molecules of DNA at a high speed and accuracy. Substantial validation of our technology has already been completed and the first steps towards platform optimisation and commercialisation are underway.

Management Team

Senior R&D Team

Board Members


Angel Investors

Depixus has strong backing from a group of very experienced angel investors, several of whom are veterans of the sequencing industry.


The company is also supported financially via a variety of other partnerships, grants, and awards

Venture Capital

Arix Bioscience Limited is a global healthcare and life science company. Headquartered in London and with an office in New York, Arix Bioscience sources and develops businesses addressing medical innovation at all stages of development and is supported with access to breakthrough academic science.